Twinrix: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 14: | Line 14: | ||
TWINRIX, HAVRIX and ENGERIX-B are registered [[trademark]]s of | TWINRIX, HAVRIX and ENGERIX-B are registered [[trademark]]s of | ||
[[GlaxoSmithKline]]; if the same vaccine is available from others, it will have another name. | [[GlaxoSmithKline]]; if the same vaccine is available from others, it will have another name. | ||
==References== | |||
{{reflist|2}} | |||
[[Category:Vaccines]] | [[Category:Vaccines]] | ||
Revision as of 15:51, 2 January 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Twinrix is a vaccine against hepatitis A and hepatitis B. Twinrix is administered over three doses.
The name was created because it is a mixture of two earlier vaccines - Havrix, an inactivated-virus Hepatitis A vaccine, and ENGERIX-B, a recombinant Hepatitis B vaccine.
The CDC reports that clinical trials found the following levels of protection against Hep A and Hep B one month after each dose[1]:
A: 93.8% 98.8% 99.9%
B: 30.8% 78.2% 98.5%
GlaxoSmithKline claims that its studies found 70% of subjects had antibodies against hepatitis B a month after just the first dose, however.[2]
TWINRIX, HAVRIX and ENGERIX-B are registered trademarks of GlaxoSmithKline; if the same vaccine is available from others, it will have another name.